Tech Company Financing Transactions
ProfoundBio Funding Round
ProfoundBio secured a $112 million Series B investment round on 2/13/2024. Investors included Ally Bridge Group, Janus Henderson Investors and LifeSci Venture Partners.
Transaction Overview
Company Name
Announced On
2/13/2024
Transaction Type
Venture Equity
Amount
$112,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to support development of its differentiated clinical-stage ADC pipeline, including the planned pivotal trial of rinatabart sesutecan (Rina-S).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
401 Terry Ave N
Seattle, WA 98109
USA
Seattle, WA 98109
USA
Phone
Undisclosed
Website
Email Address
Overview
ProfoundBio is a clinical stage biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer. Built on innovative technology platforms, ProfoundBio has developed a pipeline consisting of multiple candidates that are currently in discovery, preclinical development, and clinical stage targeting a broad range of tumors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Baiteng Zhao
Chief Medical Officer
Naomi Hunder
Chief Operating Officer
Erin Lavelle
Chief Scientific Officer
Zhu Chen
VP - Bus. Development
Kevin Hambly
VP - Bus. Development
Tae Han
VP - Manufacturing
Xiao Shang
Browse more venture capital transactions:
Prev: 2/13/2024: SQCDP venture capital transaction
Next: 2/14/2024: Fordefi venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs